Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oz Optics Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This portfolio is managed by a single distinct examiner and is situated within a sole distinct art unit. The busiest examiner, SALVOZA, M FRANCO G, is responsible for 1 pending office action.
With a single pending office action, the prosecution footprint is minimal and highly specific. The reliance on a sole distinct examiner, SALVOZA, M FRANCO G, means that the success of the current Biotechnology & Pharmaceuticals filings depends on a single individual's interpretation. Furthermore, the involvement of only a single distinct art unit suggests that the technical subject matter is being reviewed within a very specific regulatory or examination niche. Practitioners should prepare for a prosecution environment where no alternative examiner perspectives are available to influence the current trajectory. The singular focus on a sole art unit also implies a very specific technical classification for the applicant's current intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17238466 | VIRUS DETECTION PIPELINE | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17238466 | VIRUS DETECTION PIPELINE | SALVOZA, M FRANCO G | 1672 | §112 | Non-Final OA | — | Pending | Apr 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOz Optics Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
M Franco G Salvoza has the most, with 1 of Oz Optics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
